A fluorescence based sensor assay that monitors general protein aggregation in human cells by Pereira, Marisa et al.
Protein Aggregation www.biotechnology-journal.com
BIOTECH METHODA Fluorescence-Based Sensor Assay that Monitors
General Protein Aggregation in Human CellsMarisa Pereira, Diogo Tome, Ana S. Domingues, Ana S. Varanda, Cristiana Paulo,
Manuel A. S. Santos, and Ana R. Soares*Protein conformational disorders are characterized by disruption of protein
folding and toxic accumulation of protein aggregates. Here we describe a
sensitive and simple method to follow and monitor general protein aggrega-
tion in human cells. Heat shock protein 27 (HSP27) is an oligomeric small
heat shock protein that binds and keeps unfolded proteins in a folding
competent state. This high specificity of HSP27 for aggregated proteins can
be explored to monitor aggregation in living cells by fusing it to a fluorescent
protein as Green Fluorescent Protein (GFP). We have constructed a HeLa
stable cell line expressing a HSP27:GFP chimeric reporter protein and after
validation, this stable cell line is exposed to different agents that interfere
with proteostasis, namely Arsenite, MG132, and Aβ-peptide. Exposure to
proteome destabilizers lead to re-localization of HSP27:GFP fluorescence to
foci, confirming that our reporter system is functional and can be used to
detect and follow protein aggregation in living cells. This reporter is a
valuable tool to setup wide-genetic screens to identify genes and pathways
involved in protein misfolding and aggregation.1. Introduction
The accumulation of protein aggregates is a common feature of
protein conformational disorders and is generally correlated
with the onset of diseases, such as amyotrophic lateral sclerosis
(ALS), Alzheimer’s (AD), Parkinson’s (PD), Huntington’s (HD)
disease, and other age-related diseases (ARD).[1–5] Aggregation
of proteins like amyloid-beta peptide (Aβ), α-synuclein (α-syn), or
huntingtin (Htt) is commonly found in AD, PD, and HD,
respectively.[6–8] Aggregates of non-amyloid proteins areM. Pereira, D. Tome, A. S. Domingues, Dr. A. S. Varanda, C. Paulo,
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diseases. For example, aggregation of
superoxide dismutase 1 (SOD-1) is linked
to ALS[9] and α1-antitrypsin mutants ag-
gregate in the endoplasmic reticulum of
hepatocytes leading to liver-disease on-
set.[10] Moreover, evidences in different
animal models indicate that widespread
protein aggregation increases with aging.
In Caenorhabditis elegansCaenorhabditis ele-
gans there is accumulation of several
proteins through the lifespan, including
homologs of protein aggregates found in
AD and ALS.[11,12] In mice hearts multiple
proteins also aggregate with age and are
linked to AD,[13] whereas post-mortem
healthy human-aged brains show abnor-
mal accumulation of tau, Aβ, and α-syn
inclusions.[14]
Different in vitro and in vivo protein
misfolding/aggregation monitoring strate-
gies have been developed in recent years.Thioﬂavin (ThT) is a molecular probe that is commonly used to
detect amyloid ﬁbrils, in particular β-sheet-rich structures of
amyloid.[15–17]. Fluorescent reporter proteins (GFP, YFP) have
been fused to the C- or N-terminus of target proteins, allowing
monitoring the aggregation status of such proteins by
microscopy or ﬂow cytometry.[17] GFP fused to the C-terminus
of Aβ40 and Aβ42 peptides is used to screen Aβmutant peptide
libraries expressed in Escherichia coliEscherichia coli and to
identify variants with different aggregation propensity[18,19] and
toxicity.[1] In mammalian cells, an eGFP folding sensor of SOD1
is used to identifymutants with distinct aggregation propensities
and increased toxicity.[20] Fireﬂy luciferase mutants fused to
EGFP have also been used as aggregation sensors in both cells
and in animalmodels, asC. elegans.[21] Also, Htt-GFP sensors are
used to study the impact of expanded polyglutamine (PolyQ)
chains on protein aggregation and cell viability, which is relevant
to characterize HD.[22] More recently, a ﬂuorogenic aggregation
prone Halo-tag mutant was developed and is a valuable tool to
evaluate drug-induced proteome stress.[23]
Although valuable, most of the available protein aggregation
sensors are limited to monitor speciﬁc proteins. With this in
mind, we have developed a protein aggregation sensor that can
be used to monitor general protein aggregation in human cells
and we have established a stable cell line to test it in multiple
physiological conditions. For this, we took advantage of the
observation that the small heat shock protein 27 (HSP27), alsoed by Wiley-VCHVerlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.biotechnology-journal.comknown as HSPB1, is efﬁciently recruited by misfolded proteins.
HSP27 binds to misfolded proteins forming a chaperone-
substrate complex that permits refolding by larger ATP-
dependent chaperones, namely HSP70 and HSP90 or directing
proteins for degradation.[24] Therefore, we hypothesized that
HSP27 could be used to monitor protein misfolding and
protein aggregation in different physiological conditions and
pathologies.
Here we show the development of a human HSP27:GFP
sensor and a HeLa cell line expressing it in a stable manner. We
demonstrate that this sensor is a valuable tool to identify
different protein misfolding/aggregation promoting conditions
and can be used in ﬂuorescence-based genetic screens to identify
novel therapeutic targets and drug candidates that modulate
protein aggregation.2. Experimental Section
2.1. Protein Aggregation Sensor
The humanHSP27 promoter and coding region without the stop
codon were ampliﬁed from genomic DNA (gDNA) obtained
from HeLa cells. gDNA was isolated from 106 cells using the
NZY tissue gDNA isolation kit from NZYTech, following the
manufacturer’s protocol. The HSP27 promoter and coding
region were ampliﬁed by PCR, using Pfu DNA polymerase.
Ampliﬁed DNA was cloned at the MluI and XhoI sites of the
pcDNA3.1() vector (forward primer: 50-CGACGCGTGTTG-
TATGCCCCAAC-30; reverse primer: 50-CCGCTCGAGCT
TGGCGGCAGTCTC-30). Ligation of the HSP27 insert was
performed overnight and JM109 competent cells were trans-
formed with the plasmid. Clones were replated and subjected to
PCR to conﬁrm the HSP27 insertion.
eGFP was ampliﬁed from the pCS2 plasmid and cloned at XhoI
and HindIII sites of the pcDNA3.1()HSP27, originating the
pcDNA3-1()HSP27:GFP fusion vector (forward primer: 50-
CCGCTCGAGATGGTGAGCAA-30, reverse primer: 50-CCCAA
GCTTTTACTTGTACAGCT-30). Positive colonies were selected
after PCR ampliﬁcation and conﬁrmed by Sanger sequencing.2.2. Cell Transfection
HeLa cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM,Gibco), supplementedwith10%fetalbovineserum(FBS,
Sigma), 1% antibiotics (Penicillin/Streptomycin, Gibco) and
maintained in an incubator under 5% CO2/95% air at 37 C.
Cells were transfected with the pcDNA 3.1():GFP vector or the
pcDNA3.1()HSP27:GFPvector.HeLacellswereplated in1mLof
DMEMcompletemediumat a density of 2 105 cells/mL in6well
plates24hprior to transfection.Completemediumwaschanged to
mediumwithout antibiotics 1 h prior to transfection. Transfection
complexes were prepared using Lipofectamin
1
2000 following the
manufacturer’s instructions. Brieﬂy, Lipofectamin
1
2000 was
incubated with Opti-MEM for 5min at room temperature. This
mixture was incubated with 1μg of the corresponding plasmid for
20min at 37 C. After incubation, the transfection mix was added
to cells and incubated at 37 C. Transfectionmediumwas changedBiotechnol. J. 2018, 1700676 1700676 (2 of 7) © 2018 The Authors. Bioto complete medium 7h after transfection and cells were allowed
to grow for 72h before being used for further experiments. Cells
transfected with Lipofectamine
1
2000 only were used as controls.
Expression of HSP27:GFP fusion was conﬁrmed by PCR
ampliﬁcation and Sanger sequencing. 50-AAGCTGACCCT-
GAAGTTCATCTGC-30 and 50-TTACTTGTACAGCTCGTCCA-30
oligonucleotides were used to amplify GFP. 50-CGGAAATA-
CACGTGAGTCCT-30 and 50-TTACTTGTACAGCTCGTCCA-30
oligonucleotideswereused to amplifyHSP27:GFP fusion byPCR.2.3. Stable Cell Line Generation
Stable cell lines were selected using G418. After transfection,
cells were allowed to grow for 72 h. After this period, themedium
was changed for freshmedium containing 800 μgmL1 of G418.
To generate monoclonal cell lines, the polyclonal cell line
cultivated in the presence of 800 μgmL1 G418 was plated in 96
well plates at a 10 cells/mL density in 100 μL medium. Medium
with 800 μgmL1 G418 was changed every 3 days and only wells
containing one clone were expanded, originating HeLa HSP27:
GFP monoclonal stable cell lines.2.4. Reporter Assay
HeLa-HSP27:GFP cells were plated at a 2 105 cells/mL density
in 6 well plates and incubated for 24 h. Cells were then incubated
with different stress agents: 5 μM of MG132 (Sigma–Aldrich) for
18 h, 500 nM Arsenite (Sigma–Aldrich), for 30min and 15 μM of
Aβ-amyloid 1-42 (GenicBio Ltd.) for 3 h. After the incubation
period, cells were washed with 1xPBS and either collected for
protein extraction and subsequent Western blot analysis or ﬁxed
in 4% PFA.2.5. HSP27 Immunofluorescence (IF)
Fixed cells were permeabilized with 0.1% Triton X-100 for
15min. After blocking with Blocking solution (1% BSA, glycine
in PBS-T) for 30min, coverslips were incubated with a 1:100
dilution of anti-mouse HSP27 monoclonal antibody (Stress-
Marq) overnight at 4 C. After incubation, cells were washed with
PBS and incubated with Alexa-Fluor 568-conjugated goat anti-
mouse IgG antibody at a 1:200 dilution at room temperature for
2 h. Coverslips were incubated with 100 ngmL1 DAPI solution
for 15min, washed with PBS, mounted in Vectashield, and
visualized in a Zeiss AxioImagerM1 epiﬂuorescencemicroscope
using GFP, DAPI, and RFP ﬁlters. Images were acquired using
the Zeiss AxioVision software.2.6. Statistical Analysis
Data were analyzed using GraphPad Prism. The differences
between control and conditioned cells were assessed using a
Student’s unpaired t-test with post-test Dunnett’s Multiple
Comparison Test. In all cases, p-values <0.05 were considered
statistically signiﬁcant.technology Journal Published by Wiley-VCHVerlag GmbH & Co. KGaA, Weinheim
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3.1. Establishment of a Stable Cell Line Expressing HSP27:
GFP Protein Aggregation Sensor
We have previously constructed a chimeric HSPB1:mcherry
reporter sensor that successfully detects the production ofFigure 1. HSP27:GFP cloning and establishment of a HeLa cell line expressing
HSP27:GFP vector. The human HSP27 promoter and coding sequence (cs) w
the 3’ end ofHSP27 coding sequence without the stop codon, between the Xh
amplification of GFP and HSP27:GFP fusion after transfection. GFP (750 b
GFP gene was only detected in cells transfected with the pcDNA3.1()HSP27
band in all samples tested. The HSP27:GFP fusion was only detected in cells t
Fluorescence microscopy. Transfected cells were fixed and their nuclei stain
epifluorescence microscope using a 20 objective (i–iii) and a 63 objec
Expression of HSP27:GFP chimeric protein in stable HeLa HSP27:GFP cell li
the monoclonal HeLa HSP27:GFP stable cell line after G418 selection and cl
Biotechnol. J. 2018, 1700676 1700676 (3 of 7) © 2018 The Authors. Bioprotein aggregates in zebraﬁsh.[25] However, this sensor is
transient and zebraﬁsh speciﬁc. In order to identify
misfolding conditions in human cells, we have developed
now a human speciﬁc HSP27:GFP chimeric sensor
(Figure 1A).
To construct the human HSP27:GFP chimeric protein, the
HSP27 coding region without its stop codon and 5’ ﬂankingthe HSP27:GFP sensor. A) Graphical representation of the pcDNA 3.1()
ere cloned between the MluI and XhoI restriction sites. GFP was fused to
oI and HindIII restriction sites, originating theHSP27:GFP sensor. B) PCR
p) and the HSP27:GFP fusion (1026 bp) were amplified by PCR. HSP27:
:GFP vector. C) HSP27 western blotting. HSP27 was detected as a 27 kDa
ransfected with the pcDNA3.1():HSP27:GFP vector as a 59 kDa band. D)
ed with DAPI (i and iv). Cells were observed under a Zeiss AxioImager
tive (iv–vi). Efficiently transfected cells exhibited green fluorescence. E)
ne. Expression of both HSP27 and the HSP27:GFP fusion was detected in
one expansion, whereas the Control HeLa cell line expressed HSP27 only.
technology Journal Published by Wiley-VCHVerlag GmbH & Co. KGaA, Weinheim
Figure 2. HSP27:GFP sensor validation under protein misfolding conditions. A) HSP27 immunofluorescence. Endogenous HSP27 was detected using a
primaryHSP27antibodyandasecondaryAlexaFluorantibody (ii, v, andviii).HSP27:GFP fusionwasdetectedbydirect observationunder theepifluorescence
microscope using aGFP filter (i, iv, and vii). Images were captured in separate channels (RFP andGFP) andmerged using Image J to analyze co-localization
between endogenous HSP27 and the fusion protein (iii, vi, and ix). Cells were observed in unstressed conditions (i–iii), after oxidative stress induction by
arsenite (iv–vi) andafterproteasome inhibitionbyMG132 (vii–ix). Arrows indicate co-localizationof endogenousHSP27 fociwithHSP27:GFP foci generated
afterstressexposure, indicatingrelocalizationofHSP27 tocellular locationswhereproteinmisfolding/aggregationoccured.B)HSP27WesternblotofaHeLa
HSP27:GFP stable cell line under stress conditions. BothHSP27 andHSP27:GFP fusion expression increased significantly after proteasome inhibitionwith
MG132. GADPH was used as housekeeping gene. Error bars represent the standard deviation of at least three independent replicates. Units are relative to
control sample in percentage. Data analysis was performed using Student’s unpaired t-test ( p< 0.05; p< 0.01).
www.advancedsciencenews.com www.biotechnology-journal.comregion containing the promotor were ampliﬁed as a 1900 bp
product from HeLa cells gDNA preparations.
After ampliﬁcation of the HSP27 promotor and coding
region, the template was inserted in the pcDNA3.1() vector.
The HSP27 promoter replaced the plasmid CMV ubiquitous
promotor to prevent constitutive expression of the sensor. JM109
cells were transformed with the resulting plasmid and positive
clones containing the pcDNA3.1():HSP27 vector were selected
and used for subsequent GFP cloning to originate the pcDNA 3.1
():HSP27:GFP vector. In parallel, GFP was cloned in the
original pcDNA3.1(), originating the pcDNA3.1():GFP
vector. Positive clones of both vectors were identiﬁed by PCR
and validated by Sanger sequencing.
To generate a stable cell line expressing the HSP27:GFP
chimeric protein, HeLa cells were transfected with the pcDNA
3.1():HSP27:GFP vector, using Lipofectamine1 2000 as the
transfection reagent. HeLa cells transfected with Lipofectamine
1
only and HeLa cells transfected with the pcDNA3.1():GFP
vector were used as controls. As expected, GFP was PCR
ampliﬁed from all cells transfected with either the pcDNA3.1():
GFP vector and the pcDNA 3.1():HSP27:GFP vector, as a
750 bp DNA fragment (Figure 1B). The HSP27:GFP fusion
could only be ampliﬁed from cells transfected with the
pcDNA3.1():HSP27:GFP vector (Figure 1B), indicating that
these cells were efﬁciently transfected with the chimeric sensor.
To conﬁrm that the HSP27:GFP sensor protein was expressed
after transfection, Western blotting using a HSP27 antibody was
performed (Figure 1C). As HSP27 is constitutively expressed, it
was detected by Western blotting in all cell lines tested, namely
HeLa cells transfected with Lipofectamine
1
only, HeLa cells
transfected with pcDNA3.1():GFP and all the replicates
transfected with the pcDNA3.1():HSP27:GFP sensor. An extraBiotechnol. J. 2018, 1700676 1700676 (4 of 7) © 2018 The Authors. Bioband of 59 kDa corresponding to the HSP27:GFP fusion was
only detected in cells transfected with pcDNA3.1():HSP27:
GFP, conﬁrming that the chimeric protein was expressed after
transfection in HeLa cells. To further conﬁrm the ﬂuorescent
sensor expression, cells were ﬁxed and analyzed by epiﬂuor-
escence microscopy after transfection (Figure 1D). Nuclei were
stained with DAPI (Figure 1D i and iv). Cells efﬁciently
transfected and expressing the sensor exhibited GFP ﬂuores-
cence (Figure 1D ii, iii, v, and vi).
After transfection conﬁrmation, stable, monoclonal HeLa cell
lines expressing HSP27:GFP fusion, named HeLa HSP27:GFP,
were established by G418 selection. Expression of the chimeric
protein in the stable clones was conﬁrmed by Western blotting
(Figure 1E).3.2. HSP27:GFP Sensor Validation as a Protein Misfolding
Sensor
After stable cell line generation, the ability of the sensor to be used
as a general protein aggregation reporter was evaluated.
Monoclonal HeLa HSP27:GFP cells were exposed to different
proteome stressors to verify if relocalization ofﬂuorescence to foci
occurred – an indicative of the functionality of the ﬂuorescence
sensor.HSP27IFwas alsoperformed toanalyze theco-localization
betweenHSP27 and theﬂuorescent chimeric protein (Figure 2A).
Unstressed cells showed even distribution of GFP throughout
the cytoplasm, which was also in accordance with HSP27
expression observed by IF (Figure 2A i–iii).
Cells exposed to Arsenite, a known oxidative stress inducer
that elicits the cellular stress response, by translation initiation
inhibition and formation of stress granules (SGs) [26] displayedtechnology Journal Published by Wiley-VCHVerlag GmbH & Co. KGaA, Weinheim
Figure 3. HSP27:GFP detects general protein aggregation. Confocal microscopy. HeLa HSP27:GFP cells were fixed, the nuclei stained with DAPI and
observed under a Zeiss Confocal microscope in control conditions (i–iii), after proteasome inhibition (iv–vi) and after incubationwith an aggregation prone
amyloid peptide (Aβ-1-42) (vii–ix). Images were captured in separate channels using different lasers (Diode for DAPI and Argon for GFP detection) and
mergedusing Image J. Arrows indicate the formationofHSP27:GFP foci after stress exposure, indicating that proteinmisfolding/aggregationwasoccurring.
www.advancedsciencenews.com www.biotechnology-journal.comdiscrete HSP27:GFP foci which co-localized with HSP27 foci, in
particular near and inside the nucleus (Figure 2A iv–vi).
Formation of foci was expected after exposure to Arsenite, as
recent data indicate that misfolded proteins also accumulate in
SGs in human cells. For example, ALS-variants of SOD-1 have
been found accumulated in SGs that also contain chaperones,
including HSP27.[27] However, SGs induced by Arsenite are not
greatly enriched in HSP27 and are highly dynamic,[28] which
may explain the detection of only discrete foci. A similar
distribution of SGs after Arsenite treatment was observed in a
previous study using HeLa cells and the same exposure
conditions, corroborating our data.[29]
Cells were also exposed to MG132, a potent proteasome
inhibitor, to induce the accumulation of aggregated proteins inBiotechnol. J. 2018, 1700676 1700676 (5 of 7) © 2018 The Authors. Biocells. This includes accumulation of misfolded and aberrant
proteins, that can constitute up to a third of newly synthesized
polypetides. This elicits, among others, the expression of heat
shock proteins, including HSP27.[30] Our data showed formation
of HSP27:GFP foci after proteasome inhibition. This was
accompanied by the detection of Hsp27 foci by IF that co-
localized withHSP27:GFP foci (Figure 2A vii–ix), demonstrating
that HSP27 was recruited to the misfolded proteins accumulat-
ing in the cytoplasm. Upon transient transfection of a Hsp27-
GFP protein in HEK293T cells, cells treated with a proteome
destabilizer also exhibited the formation of ﬂuorescence
puncta,[23] similarly to our observations, conﬁrming that
Hsp27 is a global aggregation sensor at the cellular level. In
addition to this, western blot analysis showed that bothtechnology Journal Published by Wiley-VCHVerlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.biotechnology-journal.comendogenous HSP27 and the HSP27:GFP sensor expression
signiﬁcantly increased after proteasome inhibition (Figure 2B).3.3. HSP27:GFP Sensor Detects a Wide Spectrum of
Aggregated Proteins
To conﬁrm that our protein aggregation sensor could be used to
detect protein aggregates belonging to the amyloid class, HeLa
HSP27:GFP cells were incubated with a synthetic Aβ-amyloid 1-
42. This peptidemimics one of themajor components of amyloid
plaques that accumulate in AD patient’s neurons. After incuba-
tion, cells were observed by confocal microscopy and compared
withunstressed cells andcells exposed to theproteasome inhibitor
MG132 (Figure 3). Similarly to what was observed in Figure 2,
unstressed cells expressed HSP27:GFP homogenously in the
cytoplasm (Figure 3i–iii). After proteasome inhibition, numerous
ﬂuorescent foci were detected in different cytoplasmic locations
and also in the nucleus, conﬁrming that the ﬂuorescent sensor
detected aberrant proteins that accumulated in cells due to a
decrease in protein degradation (Figure 3iv–vi). It is possible that
the foci detected in the nuclear region correspond to nucleolar
inclusions that accumulate ubiquitin, components of the
ubiquitin-proteasome system and proteins associated with
neurodegenerativediseases,namelyAtaxin-1 andMalinornuclear
transientSGs that contain stress responseproteins, includingheat
shock proteins,[31] as these structures have been identiﬁed after
proteasome inhibition with MG132.[32] After incubation and
internalization of the synthetic Aβ-amyloid 1-42 peptide, HeLa
HSP27:GFPcells showed largeﬂuorescent foci, indicating that the
sensor was able to detected intracellular amyloids (Figure 3vi, vii,
ix). These observations were conﬁrmed by comparing the protein
insoluble fractions from control cells, cells exposed toMG132 and
cells exposed to the Aβ-amyloid 1-42 peptide. After exposure to
bothMG132 andAβ-amyloid 1-42peptide therewas an increase in
insoluble proteins (Appendix and Figure S1A, Supporting
Information). To further conﬁrm that the ﬂuorescence sensor
detects aggregated amyloids, we have performed a Western blot
using an anti-β-amyloid (B-4) antibody. As expected, a 4KDa band,
corresponding to theAβ-amyloid 1-42peptidewasonly detected in
cells incubatedwith thesyntheticpeptide.Moreover,blottingof the
insoluble fraction showed that this peptide was indeed insoluble
(Appendix Figure S1B, Supporting Information).
Additionally, we used a commercial kit of aggresome
detection (Proteostat) that detects aggresome-like inclusion
bodies in cells. As expected, unstressed HeLa HSP27:GFP cells
showed a basal Proteostat signal only, indicating that the level of
aggresomes was very low, which is supported by the homoge-
nous distribution of the HSP27:GFP sensor in the cell’s
cytoplasm (Appendix Figure S2i–iv, Supporting Information).
After Arsenite exposure, discrete HSP27:GFP foci formed, but
only a fraction of cells were Proteostat positive. Similar
observations were made after MG132 exposure (Appendix
Figure S2v, vi, viii, ix, Supporting Information), indicating that
our sensor was more effective in detecting different misfolding
occurrences. But, there was strong co-localization of the HSP27:
GFP and Proteostat signals after incubation with Aβ-amyloid 1-
42 peptide. This was expected as Proteostat detects intracellular
amyloid-like deposits with high speciﬁcity.[33]Biotechnol. J. 2018, 1700676 1700676 (6 of 7) © 2018 The Authors. Bio4. Conclusion
The objective of this work was to develop a HSP27:GFP sensor to
detect protein misfolding and protein aggregation, indepen-
dently of its nature and without the need of additional IF or
immunocytochemistry. Most protein aggregates are amyloids,
but other classes of proteins also aggregate in speciﬁc conditions
and may escape detection with existing methods. Our results
show that our sensor detects general protein aggregation in an
easy manner and has advantages relatively to the available
protein-aggregation reporters.
Oursensor is avaluable tool for thedevelopmentofﬂuorescence-
based screens to identify both genes that affect proteostasis and
chemical compounds that lead toproteindestabilization.Ourstable
cell line expressing the ﬂuorescent protein misfolding sensor,
allows performing experiments where cellular conditions can be
manipulated and observed in real time, representing a valuable
asset to understand proteome stability dynamics. Since different
human stable cell lines can be established using the HSP27:GFP
sensor, it is an important new tool to identify modulators of
proteostasis and, consequently, therapeutic targets that can be
applied to several protein conformational disorders.Abbreviations
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